Literature DB >> 14762491

Hemolytic disease of the newborn due to anti-U.

Marcia Cristina Zago Novaretti1, Eduardo Jens, Thiago Pagliarini, Silvia Le o Bonif cio, Pedro Enrique Dorlhiac-Llacer, Dalton de Alencar Fischer Chamone Dd.   

Abstract

Anti-U is a rare red blood cell alloantibody that has been found exclusively in blacks. It can cause hemolytic disease of the newborn and hemolytic transfusion reactions. We describe the case of a female newborn presenting a strongly positive direct antiglobulin test due to an IgG antibody in cord blood. Anti-U was recovered from cord blood using acid eluate technique. Her mother presented positive screening of antibodies with anti-U identified at delivery. It was of IgG1 and IgG3 subclasses and showed a titer of 32. Monocyte monolayer assay showed moderate interaction of Fc receptors with maternal serum with a positive result (3.1%). The newborn was treated only with 48 hours of phototherapy for mild hemolytic disease. She recovered well and was discharged on the 4th day of life. We conclude that whenever an antibody against a high frequency erythrocyte antigen is identified in brown and black pregnant women, anti-U must be investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14762491     DOI: 10.1590/s0041-87812003000600006

Source DB:  PubMed          Journal:  Rev Hosp Clin Fac Med Sao Paulo        ISSN: 0041-8781


  3 in total

1.  Anti-U alloimmunisation in a pregnant woman from Niger.

Authors:  Alvaro Ringressi; Sara Biagioni; Giorgio Mello; Gabriele Graziani; Federico Mecacci
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

2.  Hemolytic disease of the fetus and newborn caused by anti-D and anti-S alloantibodies: a case report.

Authors:  Rabeya Yousuf; Suria Abdul Aziz; Nurasyikin Yusof; Chooi-Fun Leong
Journal:  J Med Case Rep       Date:  2012-02-20

3.  Generation of 'designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 gene-edited human-induced pluripotent stem cells.

Authors:  Priyanka Pandey; Nanyan Zhang; Brian R Curtis; Peter J Newman; Gregory A Denomme
Journal:  J Cell Mol Med       Date:  2021-09-21       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.